AS FEATURED IN
Oral and Throat Cancer Detection Test built on
Viome platform, designated Breakthrough Device for accelerated Review by FDA
Early detection saves lives
Detecting cancer early is important. The earlier it is detected, the higher the chance of survival.
with late detection
The overall 5-year survival rate for people with late stage oral cancer is 40%3
with early detection
If diagnosed at an early stage, the overall 5-year survival rate is 84%4
of patients get
Unfortunately, with today’s practices, only 28% of patients are diagnosed at an early stage3
Reliable results that you can trust
Our CancerDetect™ - Oral & Throat test detects molecular features of oral & throat cancers even in early stages when it is more treatable. The test delivers the highest accuracy currently possible and surpasses the current standard of care - the visual and tactile exam.
Sensitivity refers to a test's ability to designate an individual with a disease as positive. A highly sensitive test means that there are few false-negative results, and thus fewer cases of the disease are missed.
Specificity refers to a test's ability to designate an individual who does not have a disease as negative. A highly specific test means that there are few false-positive results, and thus few false alarms.
Oral and Throat Cancer Detection Test
built on Viome platform, designated Breakthrough Device for accelerated Review by FDA
Inside your test collection kit
1. Banavar G, Ogundijo O, Julian C, et al. Detecting salivary host-microbiome RNA signature for aiding diagnosis of oral and throat cancer. July 2022. https://doi.org/10.1101/2022.07.30.22278239
2. Banavar G, Ogundijo O, Toma R, Rajagopal S, Lim YK, Tang K, et al. The salivary metatranscriptome as an accurate diagnostic indicator of oral cancer. NPJ Genomic Medicine. 2021;6(1):105.
3. National Cancer Institute Surveillance, Epidemiology and End Results Program. 2021. (Cancer Stat Facts: Oral Cavity and Pharynx Cancer).
4. Peacock ZS, Pogrel MA, Schmidt BL. Exploring the Reasons for Delay in Treatment of Oral Cancer. J Am Dent Assoc. 2008;139(10):1346–52.
5. Mager D, Haffajee A, Devlin P, Norris C, Posner M, Goodson J. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med. 2005 Jul 7;3:27.
6. Su SC, Chang LC, Huang HD, Peng CY, Chuang CY, Chen YT, et al. Oral microbial dysbiosis and its performance in predicting oral cancer. Carcinogenesis. 2020;42(1):127–35.
7. Wang L, Yin G, Guo Y, Zhao Y, Zhao M, Lai Y, et al. Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer. Front Cell Infect Mi. 2019;9:205.
8. Irfan M, Delgado RZR, Frias-Lopez J. The Oral Microbiome and Cancer. Front Immunol. 2020;11:591088.
9. Hatch A, Horne J, Toma R, Twibell BL, Somerville KM, Pelle B, et al. A Robust Metatranscriptomic Technology for Population-Scale Studies of Diet, Gut Microbiome, and Human Health. Int J Genomics. 2019 Jan 1;2019:1718741.
10. Shield KD, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi AK, Bray F, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. Ca Cancer J Clin. 2017;67(1):51–64.
11. Kujan O, Glenny A, Oliver R, Thakker N, Sloan P. Screening programmes for the early detection and prevention of oral cancer. Cochrane Db Syst Rev. 2006;(3).
12. Blot WJ, McLaughlin J, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;11(48):3282–7.
13. Moyer VA. Screening for Oral Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2014;160(1):55–60.
14. National Program of Cancer Registries SEER. Stat Database: U.S. Cancer Statistics Incidence Analytic file 1998–2017. United States Department of Health and Human Services, Centers for Disease Control and Prevention; 2020.